NCT02101333 (TOCITAKA) is a Phase 3 clinical trial of Tocilizumab in TAKAYASU ARTERITIS, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT02101333?

NCT02101333 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT02101333?

Interventions in NCT02101333: Tocilizumab.

What condition does NCT02101333 study?

NCT02101333 studies TAKAYASU ARTERITIS.

Is NCT02101333 still recruiting?

NCT02101333 is currently completed. Last updated 19 August 2020.

Last reviewed 2020-08-19 · How we verify

NCT02101333: TOCITAKA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

Completed Phase 3 Last updated 19 August 2020

What this trial tests

Phase 3 trial testing Tocilizumab in TAKAYASU ARTERITIS in 18 participants. Completed in 1 February 2019.

Timeline

10 June 2014

Primary endpoint
10 December 2018

1 February 2019

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	10 June 2014
Primary completion	10 December 2018
Estimated completion	1 February 2019
Sites	1 location across France

Drugs / interventions tested

Tocilizumab (tocilizumab) — full drug profile →

Conditions studied

TAKAYASU ARTERITIS — all drugs for TAKAYASU ARTERITIS →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 18 to 77, any sex, with TAKAYASU ARTERITIS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

First-line tocilizumab treatment during 6 months could permit rapid steroid-tapering and induction of remission in Takayasu arteritis (TA).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.
Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. · · 2016 · cited 474× · PMID 26633291 · DOI 10.1038/nrrheum.2015.167
Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial.
Mekinian A, Saadoun D, Vicaut E, Thietart S, et al · · 2020 · cited 27× · PMID 32943098 · DOI 10.1186/s13075-020-02311-y
Leveraging Genetic Findings for Precision Medicine in Vasculitis.
Acosta-Herrera M, González-Gay MA, Martín J, Márquez A. · · 2019 · cited 10× · PMID 31428096 · DOI 10.3389/fimmu.2019.01796
Central and Peripheral Nervous System Complications of Vasculitis Syndromes from Pathology to Bedside: Part 2-Peripheral Nervous System.
Mansueto G, Lanza G, Falleti J, Orabona P, et al · · 2023 · cited 6× · PMID 36820992 · DOI 10.1007/s11910-023-01249-3

Verify or expand the search:

Other trials of Tocilizumab

Trials testing the same drug.

NCT03787290 — Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder · Phase 2 · suspended
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02101333 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 19 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02101333.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing